Aclarion Inc (ACON) Stock Price, Trades & News

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	No Debt
Equity-to-Asset	0.95
Interest Coverage	No Debt
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-0.17	Distress Grey Safe
Beneish M-Score	-4.12	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EPS without NRI Growth Rate	95.5

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	34.29
	9-Day RSI	34.28
	14-Day RSI	36.97
	3-1 Month Momentum %	-3.66
	6-1 Month Momentum %	-41.37
	12-1 Month Momentum %	-55.99

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	19.65
	Quick Ratio	19.65
	Cash Ratio	19.27
	Days Sales Outstanding	135.57
	Days Payable	2300.68

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Shareholder Yield %	-15

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	19.48
	Operating Margin %	-11101.3
	Net Margin %	-10454.55
	EBITDA Margin %	-10324.68
	FCF Margin %	-9700
	OCF Margin %	-9474.03
	ROE %	-53.69
	ROA %	-51.11
	ROIC %	-531.66
	3-Year ROIIC %	-420.9
	ROC (Joel Greenblatt) %	-33536.89
	ROCE %	-54.58
	Moat Score	1
	Tariff Resilience Score	6

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	28.05
	PB Ratio	0.35
	Price-to-Tangible-Book	0.37
	EV-to-EBIT	-0.8
	EV-to-EBITDA	-0.82
	EV-to-Revenue	84.57
	EV-to-FCF	-0.87
	Price-to-Net-Current-Asset-Value	0.37
	Price-to-Net-Cash	0.38
	Earnings Yield (Greenblatt) %	-125
	FCF Yield %	-108.14

GF Value™

ACON

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with ACON. Try a 7-Day Free Trial to check it out.

Aclarion Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Aclarion Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings results for 2026	2026-11-12	In 137 days
Second quarter earnings results for 2026	2026-08-14	In 47 days
Guidance call for 2026	2026-06-17 08:30	2.94 (-1.34%)
General meeting for 2026	2026-06-04 14:30	3.49 (+1.75%)
First quarter earnings results for 2026	2026-05-13	3.15 (-0.32%)
Annual report for 2025	2026-03-18	3.24 (+0.62%)
Third quarter earnings results for 2025	2025-11-12	7.14 (-1.38%)
Second quarter earnings results for 2025	2025-08-14	7.09 (-5.77%)
General meeting for 2025	2025-07-07 09:30	7.45 (-2.74%)
First quarter earnings results for 2025	2025-05-15	7.16 (-4.53%)

Show

Entries

Guru Commentaries on NAS:ACON

No articles.

Press Release

	Subject	Date
	Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.	2026-03-24
	Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st	2024-11-14
	Thinking about buying stock in Panbela Therapeutics, Netflix, Qualcomm, Cyngn, or Aclarion?	2024-01-26
	Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV	2022-10-25
	Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor	2022-10-24
	Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan	2022-07-20
	Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain	2022-06-22
	Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering	2022-04-26
	Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering	2022-04-21

10/Page

Articles on Aclarion Inc

No articles.

Headlines

Jun 10, 2026

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Benzinga • 6:00am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.